

Orexo is Committed to Supporting Patients with OUD (Opioid Use Disorder)

Opioid use disorder is a chronic and treatable disease and that continues to be a constant long-term threat to people in our country. In September 2023, 12-month data showed that an estimated 114,000 Americans died from overdose.¹ Orexo is encouraged that recently the number is beginning to trend downward. In September 2024, 12-month data showed that number decreased to 87,000 deaths.¹ That is a 24% percent decrease.¹ All of us at Orexo see this downward trend as validation and hope that the work we have been doing since 2013 is helping to make a difference for the OUD epidemic in America. We have so much more work ahead of us, and we are committed to fighting OUD on this passionate journey.

Since Orexo US entered the market in 2013, our people have continued to demonstrate a steadfast commitment to helping patients, families and communities struggling with OUD to take steps toward recovery. From day one, our unwavering focus has been to help serve the needs of patients so that, along with the support of their healthcare team, they may enter a path to sustained recovery. **Orexo believes that patients struggling with OUD deserve our science, our support, and, most importantly, our understanding to aid in their journey to recovery.**

To that end, Orexo US has taken many initiatives to help support patients with OUD.

Our Offerings

- **ZUBSOLV[®]** (buprenorphine and naloxone) sublingual tablets (CIII) combine active ingredient with an innovative proprietary quick dissolve delivery technology and an abuse deterrent
 - Over 450,000 patients have been treated with ZUBSOLV from 2013 to 2024²
 - Safety and efficacy demonstrated in largest US clinical drug study conducted in OUD²
 - Six dosage strengths to provide flexibility to individualize treatment (one tablet allows titration to the most effective doses needed by each patient)
 - F1 child resistant packaging to mitigate accidental ingestion by children
 - Serialization of packaging since launch to allow for track and trace if desired by stakeholders
 - Patient preference demonstrated in head-to-head clinical study with market leader²
- **Modia[®]** is a web-based software program designed to help patients develop behavioral coping skills to manage their condition
 - Incorporates evidence-based counseling techniques
 - Provides educational information, reminders and motivational guidance
 - Conducted clinical study with over 430 subjects to assess effectiveness²
 - Conducted over 2,800 patient evaluations in real world environments²
- **MATCore[™]** is a customizable online platform designed to overcome OUD treatment barriers and increase patient engagement
 - Delivery of medication
 - Patient education, links to local resources and patient surveys
 - HCP analytics
 - Contingency Management tracking

Our Research & Development

- Over \$142 million invested in Research and Development²
 - OX124 is a high dose powder-based intranasal naloxone rescue medication under development²
 - Designed to be stable at a wide range of outdoor temperatures²
 - OX390 is a rescue medication in development for highly potent drug overdoses involving newly emerging drugs of concern²
 - OX125 is a powder-based intranasal nalmefene rescue medication in development²
 - Expected to have a prolonged half-life and longer duration of action than naloxone based rescuers²
-

Our Access Programs

- Voucher Program- provides two 15 free tablet prescriptions of any strength
 - Only OUD company (branded or generic) to offer program of this type
 - Provides medication for vulnerable patients while they wait for potential Prior Authorization from insurer, are between jobs, or have lost insurance coverage
 - Designed and administered by market leader McKesson
 - Insurance agnostic, it does not matter if patients' insurance covers ZUBSOLV
 - Over 230,000 patients have used vouchers
- Copay Program for commercially-insured and cash-paying patients
 - Designed and administered by market leader McKesson
 - Helps patients with out-of-pocket costs associated with co-pays required by insurers
 - Helps cash-paying patients with no insurance lower the cost of their prescription
 - Patients receive up to \$225 toward co-pay or cost of prescription and have no limit on number of monthly uses
- Patient Assistance Program for indigent patients with no prescription insurance
 - All healthcare providers are eligible to enroll 1 qualified patient
 - Business rules in place to ensure appropriate eligible patients and appropriate prescribing described in prescribing information
 - Administered by third party nonprofit entity, Needy Meds, Inc.
 - Patients stay in program for as long as medically and financially necessary
- Opioid Treatment Program (OTPs) discounts
 - Discounts for eligible OTPs
- Placebos (do not contain medication; offer similar taste to ZUBSOLV which are used for demonstration and under-the-tongue trial use)

Our Commitment to Advocacy

- We provide education and information to key state and national decision makers supporting responsible legislation to reduce stigma of OUD and increase appropriate access to treatment
- We publicly advocated for raising the cap/removing waiver requirement for healthcare providers
- We support open-access state policy for all products in Opioid Dependence category (eliminating prior authorizations for category in various states)
- We have negotiated 99% unrestricted commercial health insurance access in the US²
- We ran the award-winning OUD destigmatization campaign, "Out the Monster"

Orexo is relentlessly committed to helping patients with OUD and their treatment team receive the support they need for lifelong recovery.

References:

1. <https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths>
2. Orexo US, Inc. Data on File

**Questions?
Contact Orexo US, Inc. at
1-855-982-7658**